Advertisement
NTRA vs SMTI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRA is a Hold and SMTI is a Hold.
NTRA's RSI Oscillator is remaining in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 71 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 38 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.585) is normal, around the industry mean (67.298). NTRA's P/E Ratio (-230.126) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SMTI's RSI Indicator recovers from oversold territory
The RSI Oscillator for SMTI moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMTI advanced for three days, in 186 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
SMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where SMTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMTI as a result. In 59 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
SMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMTI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. SMTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMTI's P/B Ratio (36.493) is very high in comparison to the industry average of (4.964). P/E Ratio (-8.481) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.050) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.777) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NTRA | SMTI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 25 | 100 | |
SMR RATING 1..100 | 94 | 99 | |
PRICE GROWTH RATING 1..100 | 44 | 44 | |
P/E GROWTH RATING 1..100 | 71 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (4) in the Biotechnology industry is significantly better than the same rating for SMTI (80) in the null industry. This means that NTRA’s stock grew significantly faster than SMTI’s over the last 12 months.
NTRA's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for SMTI (100) in the null industry. This means that NTRA’s stock grew significantly faster than SMTI’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as SMTI (99) in the null industry. This means that NTRA’s stock grew similarly to SMTI’s over the last 12 months.
NTRA's Price Growth Rating (44) in the Biotechnology industry is in the same range as SMTI (44) in the null industry. This means that NTRA’s stock grew similarly to SMTI’s over the last 12 months.
NTRA's P/E Growth Rating (71) in the Biotechnology industry is in the same range as SMTI (98) in the null industry. This means that NTRA’s stock grew similarly to SMTI’s over the last 12 months.
| NTRA | SMTI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 76% | N/A |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 73% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 78% |
| Advances ODDS (%) | 6 days ago 79% | 6 days ago 74% |
| Declines ODDS (%) | 4 days ago 75% | 4 days ago 77% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 83% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NTRA’s FA Score shows that 2 FA rating(s) are green while SMTI’s FA Score has 0 green FA rating(s).
- NTRA’s FA Score: 2 green, 3 red.
- SMTI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NTRA’s TA Score shows that 4 TA indicator(s) are bullish while SMTI’s TA Score has 3 bullish TA indicator(s).
- NTRA’s TA Score: 4 bullish, 5 bearish.
- SMTI’s TA Score: 3 bullish, 5 bearish.
Price Growth
NTRA (@Medical Specialties) experienced а -15.45% price change this week, while SMTI (@Pharmaceuticals: Other) price change was +0.09% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.11%. For the same industry, the average monthly price growth was -5.15%, and the average quarterly price growth was +40.44%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was +4.73%, and the average quarterly price growth was +18.71%.
Reported Earning Dates
NTRA is expected to report earnings on Mar 04, 2027.
SMTI is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (-1.11% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+5.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
SMTI and
Correlation & Price change
A.I.dvisor indicates that over the last year, SMTI has been loosely correlated with A. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SMTI jumps, then A could also see price increases.
| Ticker / NAME | Correlation To SMTI | 1D Price Change % | ||
|---|---|---|---|---|
| SMTI | 100% | +1.74% | ||
| A - SMTI | 47% Loosely correlated | +3.10% | ||
| NTRA - SMTI | 45% Loosely correlated | +3.13% | ||
| MTD - SMTI | 44% Loosely correlated | +2.33% | ||
| TWST - SMTI | 44% Loosely correlated | +12.05% | ||
| IQV - SMTI | 44% Loosely correlated | +2.58% | ||
More | ||||